NCT05815186
Withdrawn
Phase 2
Phase II Study of Ladarixin and Sotorasib In Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)
Overview
- Phase
- Phase 2
- Status
- Withdrawn
- Sponsor
- NYU Langone Health
- Locations
- 1
- Primary Endpoint
- Progression Free Survival (PFS)
Overview
Brief Summary
Study record has been combined with NCT05815173. See NCT05815173 for summary.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 100 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Written informed consent, according to local guidelines, signed and dated by the participant prior to the performance of any study-specific procedures, sampling, or analyses.
- •Participant must be ≥18 years of age at the time of signature of the informed consent form (ICF).
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or
- •Histologically confirmed diagnosis of NSCLC (squamous or nonsquamous).
- •Patients with metastatic or locally advanced NSCLC who are not candidates for curative surgery or curative radiation.
- •Do not have an epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) translocation, rearranged during transfection (RET), ROS1 or other actionable molecular alterations that can be treated with FDA approved targeted agents.
- •Patients must have documentation of presence of KRASG12C mutation in tumor tissue.
- •Patients must have demonstrated progression of disease following treatment with anti-PD (L)-1 with or without platinum-based chemotherapy.
- •Participants must have at least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.
- •Tumor lesions that have been irradiated ≥4 weeks before the start of treatment, and have subsequently had documented progression, may be chosen as target lesions in the absence of measurable lesions that have not been irradiated.
Exclusion Criteria
- •History (≤1 years) or presence of hematological malignancies except stable chronic lymphocytic leukemia.
- •History (≤1 years) of other cancer that is histologically distinct from the cancers under study, except for cervical carcinoma in situ, ductal carcinoma in situ, prostatic intraepithelial neoplasia, superficial non-invasive bladder tumors, or curatively treated stage I non-melanoma skin cancer.
- •Known serious allergy to ladarixin, sotorasib, or excipients (e.g., microcrystalline cellulose).
- •History (≤6 months before the start of treatment with the study drugs) of severe autoimmune disease (including ≥ Grade 3 or recurrent Grade 2 immune-related AEs of prior immuno-oncology therapy) or autoimmune disorder that requires chronic systemic corticosteroid treatment at immunosuppressive doses (prednisone \>10 mg/day or equivalent).
- •Brain or spinal metastases, except if treated by surgery or surgery plus radiotherapy or radiotherapy alone, with no clinical evidence of progression or hemorrhage for ≤7 days before the start of treatment with the study drugs, and has not received any systemic corticosteroids for ≥7 days before the start of treatment with the study drugs.
- •History (≤6 months before the start of treatment with the study drugs) of pericarditis (any grade) or pericardial effusion (Grade ≥2).
- •History of interstitial lung disease, radiation pneumonitis which required steroid treatment, idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis, or organizing pneumonia.
- •Active infection requiring systemic treatment at the start of treatment in this trial. A washout period of 7 days after the last dose of antibiotics prior to first dose of study drug is required.
- •History of seropositive status for human immunodeficiency virus (HIV) at any time before the start of treatment as determined by presence of anti-HIV-1 or anti-HIV-2 antibodies.
- •- Note: Testing for seropositive status during Screening will be at the discretion of the investigator in participants without previously reported results.
Arms & Interventions
Advanced NSCLC Patients
Experimental
Patients with KRASG12C mutant NSCLC will receive ladarixin and sotorasib in combination.
Intervention: Sotorasib (Drug)
Advanced NSCLC Patients
Experimental
Patients with KRASG12C mutant NSCLC will receive ladarixin and sotorasib in combination.
Intervention: Ladarixin (Drug)
Outcomes
Primary Outcomes
Progression Free Survival (PFS)
Time Frame: Up to End of Survival Follow-Up (Up to Month 36)
PFS is the amount of time (months) from initial treatment to disease progression or death from any cause.
Secondary Outcomes
- Percent of Participants who Experience Grade 4 Treatment-Related Adverse Events per CTCAE 5.0(Up to End of Survival Follow-Up (Up to Month 36))
- Percent of Participants who Experience Grade 2 Treatment-Related Adverse Events per CTCAE 5.0(Up to End of Survival Follow-Up (Up to Month 36))
- Percent of Participants who Experience Grade 1 Treatment-Related Adverse Events per CTCAE 5.0(Up to End of Survival Follow-Up (Up to Month 36))
- Percent of Participants who Experience Unconfirmed Complete Response (UCR)(Up to End of Survival Follow-Up (Up to Month 36))
- Percent of Participants who Experience Complete Response (CR)(Up to End of Survival Follow-Up (Up to Month 36))
- Overall Survival (OS)(Up to End of Survival Follow-Up (Up to Month 36))
- Percent of Participants who Experience Grade 5 Treatment-Related Adverse Events per CTCAE 5.0(Up to End of Survival Follow-Up (Up to Month 36))
- Percent of Participants who Experience Grade 3 Treatment-Related Adverse Events per CTCAE 5.0(Up to End of Survival Follow-Up (Up to Month 36))
- Percent of Participants who Experience Partial Response (PR)(Up to End of Survival Follow-Up (Up to Month 36))
- Percent of Participants who Experience Unconfirmed Partial Response (PR)(Up to End of Survival Follow-Up (Up to Month 36))
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
Ladarixin With Sotorasib in Advanced NSCLCAdvanced Non-small Cell Lung Cancer With KRAS G12C MutationNCT05815173NYU Langone Health40
Terminated
Phase 1
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDSMyelodysplastic SyndromeNCT02706899Seagen Inc.19
Completed
Phase 2
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Indolent Adult Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaNCT00764517OHSU Knight Cancer Institute57
Completed
Phase 1
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid TumorsCentral Nervous System Embryonal Tumor With Rhabdoid FeaturesCentral Nervous System Embryonal Tumor, Not Otherwise SpecifiedCentral Nervous System GanglioneuroblastomaEmbryonal Tumor With Multilayered Rosettes, C19MC-AlteredPineoblastomaPrimary Central Nervous System NeoplasmRecurrent Childhood Central Nervous System Embryonal NeoplasmRecurrent Malignant Solid NeoplasmRecurrent MedulloblastomaRecurrent NeuroblastomaRecurrent RhabdomyosarcomaRefractory Malignant Solid NeoplasmRefractory MedulloblastomaRefractory NeuroblastomaRefractory RhabdomyosarcomaNCT02095132National Cancer Institute (NCI)76
Recruiting
Phase 2
Study of the Combination Dostarlimab With Niraparib In Patients With Penile CarcinomaPenile CarcinomaNCT05526989H. Lee Moffitt Cancer Center and Research Institute25